Researchers pinpoint a cellular process called 'clonal hematopoiesis' as a new risk factor for cardiovascular problems. In ...

To the known risk factors for cardiovascular disease-;high blood pressure, high cholesterol, diabetes, overweight and obesity, smoking, and physical inactivity-;a new one has to be added ...

A type of zooplankton, Daphnia pulex (a.k.a. the water flea) is a microscopic crustacean whose unique reproduction habits ...

Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...

Cancer cells are driven by the same imperative guiding all living things: to grow, survive and reproduce. Although cancer's ...

Shares of Achilles Therapeutics plc (NASDAQ:ACHL) surged Thursday after the biotechnology firm revealed plans to discontinue ...

Achilles to discontinue development of TIL-based cNeT therapy––Cash position of $95.1 million as of June 30, 2024––BofA Securities engaged to ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

A review examines the prevailing theory of cancer evolution. The authors highlight both practical and theoretical limitations of the clonal model of cancer evolution and propose areas for improving ...